- Free from Publisher RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study
at 82 US sites was performed with 336 randomized patients. In all, 272 patients
completed the study. The intent-to-treat population baseline was 53 ± 10 ... Cited by 637 - Related articles - All 6 versions
- Free from Publisher DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 543 - Related articles - All 11 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 454 - Related articles - BL Direct - All 13 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 330 - Related articles - BL Direct - All 7 versions
- Free from Publisher B Ahrén, R Gomis, E Standl, D Mills, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1%
and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change
from a baseline of 7.9 ± 0.1% in patients given placebo (between-group ... Cited by 310 - Related articles - BL Direct - All 8 versions
- ►physiology.org JJ Holst, J Gromada - American Journal of Physiology- Endocrinology And …, 2004 - Am Physiological Soc The available evidence suggests that about two-thirds of the insulin response to
an oral glucose load is due to the potentiating effect of gut-derived incretin
hormones. The strongest candidates for the incretin effect are ... Cited by 180 - Related articles - BL Direct - All 4 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 173 - Related articles - All 25 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among
193 outpatients with type 2 diabetes. The mean age was 56.6 years and the ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in experimental and clinical …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP
Mohana Priya, M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G.
Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
